Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (155)	2/17/1999 12:39:00 PM
From: jeffbas	Read Replies (1) \| Respond to of 3158

Re: "even my $825m seems low to me, perhaps by a factor of three or four" To what extent do we also need to adjust the above sentence back down again by a factor of perhaps 1/3 or 1/4 (to the original starting point number) for the fact that there are several competing compounds out there that may get to market sooner including especially the "next generation" one (to angiostatin and endostatin) just licensed by GZMO from Children's Hospital, which may be more effective and also get to market sooner because of Genzyme's far superior resources available to GZMO.